The circulation of documents related to a patent infringement lawsuit can lead to negative sentiment among investors, potentially causing a decrease in Moderna's stock price in the short term. The direct involvement of Moderna in this legal issue, as indicated by the lawsuit from Arbutus/Genevant, makes this news highly relevant and important for investors, impacting the stock's performance.